The DOI matches its Crossref record.
Recent Declines in Hormone Therapy Utilization and Breast Cancer Incidence: Clinical and Population-Based Evidence
Abstract
TO THE EDITOR: Long-term use of estrogen- or progestincontaining hormone therapies (HT) is well recognized to be associated with increased risk of breast cancer both in observational studies and the Women’s Health Initiative (WHI) randomized trial. 1 After the early termination of the trial in July 2002 and the subsequent media coverage, reports from clinical series indicated immediate declines of 28% to 46% in prevalences of HT and estrogen-only (ET) use. 2,3 The population-level impact of these declines on breast cancer are uncertain given the 2- to 3-year lag time between diagnosis and data availability in cancer registries. To better understand the possible impact from changes in HT on breast cancer in larger populations, we compared recent secular trends in HT use and breast cancer incidence in available clinical and population-based data resources, including recently released cancer registry data for the year 2004. We calculated the annual prevalence of HT use and the annual incidence of invasive breast cancer for the period from 1994 to 2003 for women ages 50 to 74 years in Kaiser Permanente’s (Oakland, CA) Northern California region (KPNC), a large integrated health-delivery system from which computerized pharmacy, membership, and hospital cancer registry data were obtained. Women filling at least two prescriptions (generally constituting 90 days per prescription) of HT or ET in any calendar year were considered users for that year. First primary invasive breast cancer (International Classification of Disease–Oncology, 3rd edition [ICDO-3] 4 site 50.0-50.9) diagnoses were identified, with histologic subtypes defined as ductal (ICD-O-3 codes 8500), or “with lobular component” (ICD-O-3 codes 8520, 8522, 8524). Yearly denominators included women who were KPNC members for at least 11 months of
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The Decrease in Breast-Cancer Incidence in 2003 in the United States
Ravdin, P. M., Cronin, K. A., Howlader, N., Berg, C. D., Chlebowski, R. T., Feuer, E. J., Edwards, B. K., & Berry, D. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr070105 · Cited by 982
Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in Postmenopausal Women
Chlebowski, R. T., Anderson, G. L., Gass, M., Lane, D. S., Aragaki, A. K., Kuller, L. H., Manson, J. E., Stefanick, M. L., Ockene, J., Sarto, G. E., et al. (2010) · JAMA · doi:10.1001/jama.2010.1500 · Cited by 567
Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women
Chlebowski, R. T., Kuller, L. H., Prentice, R. L., Stefanick, M. L., Manson, J. E., Gass, M., Aragaki, A. K., Ockene, J. K., Lane, D. S., Sarto, G. E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0807684 · Cited by 472
The Controversial History of Hormone Replacement Therapy
Cagnacci, A., & Venier, M. (2019) · Medicina · doi:10.3390/medicina55090602 · Cited by 298
Eskens, F. A. L. M., Mom, C. H., Planting, A. S. T., Gietema, J. A., Amelsberg, A., Huisman, H., van Doorn, L., Burger, H., Stopfer, P., Verweij, J., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604108 · Cited by 234
Metadata
- Authors
- Clarke, C. A., Glaser, S. L., Uratsu, C. S., Selby, J. V., Kushi, L. H., & Herrinton, L. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-11-20
- Volume
- 24
- Issue
- 33
- Pages
- e49-e50
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2163283029
- Cited by
- 160
- References
- 0
- FWCI
- 14.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recent Declines in Hormone Therapy Utilization and Breast Cancer Incidence: Clinical and Population-Based Evidence. https://app.cochat.ai/papers/10.1200/jco.2006.08.6504
- The paper
- Clarke, C. A., Glaser, S. L., Uratsu, C. S., Selby, J. V., Kushi, L. H., & Herrinton, L. J. (2006). Recent Declines in Hormone Therapy Utilization and Breast Cancer Incidence: Clinical and Population-Based Evidence. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2006.08.6504
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.